InvestWiser

Iconovo

ICONasdaq StockholmHealthcareMarket value 98 m SEK
1.02SEK −1.2%
last day · Price as of 19 November 2026

The answer first

Does Iconovo beat the market?

No, Iconovo has not beaten the market over the last year.

Iconovo−30.1%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 29% of Nordic stocks

    • Quality82
    • Value22
    • Trend19

    No. 105 of 195 in healthcare

Max for seven days

Follow Iconovo with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Iconovo

From today, at a price of 1.02 SEK. Write why you follow Iconovo, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Iconovo

Your first answer is free, no account needed.

Do you own Iconovo, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Iconovo and a few more. Free, no card.

Past year against the exchange and Super Stock
Iconovo−34.0%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Iconovo has fallen 30.1% over the past year, including dividends.
  • Overall, Iconovo ranks better than 29% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 98.3%. The price is 98.8% below its peak now.

What do analysts think of Iconovo?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

29

Quality, value and trend together. Better than 29% of Nordic stocks.

No. 105 of 195 in healthcare

Quality82
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 48 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.05
  • Asset turnoverSales divided by everything the company owns0.02
  • Return on equityProfit divided by equity−26.1%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value22
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 92 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.7
  • P/SPrice divided by sales39.8
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend19
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 129 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−15.1%
  • 6 months−12.1%
  • 9 months−9.7%
  • 12 months−30.1%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+0.5%
3 years, per year
−51.7%
5 years, per year
−57.9%
Year to date
−10.5%
Largest fall, 3 years
−98.3%
From a peak to the bottom
From the peak now
−98.8%
How far the price is from the peak
Volatility, 1 year
56.2%
How much the price swings over a year
Beta, 1 year
0.43
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Iconovo

One fund we follow owns Iconovo. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About Iconovo

Iconovo is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 12 employees.

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for interstitial lung disease. The company was incorporated in 2013 and is headquartered in Lund, Sweden.

See the full analysis of Iconovo.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market